|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003438,
umls-concept:C0178602,
umls-concept:C0205225,
umls-concept:C0392806,
umls-concept:C0439608,
umls-concept:C0439851,
umls-concept:C0442027,
umls-concept:C0543467,
umls-concept:C1552596,
umls-concept:C1708528,
umls-concept:C1861172,
umls-concept:C1947931,
umls-concept:C2603343,
umls-concept:C2825027
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-7-31
|
|
pubmed:abstractText |
YM150, a new oral direct factor Xa inhibitor is used as prophylaxis for venous thromboembolism (VTE), a well-known risk after orthopaedic surgery.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1538-7933
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1660-5
|
|
pubmed:meshHeading |
pubmed-meshheading:17663737-Administration, Oral,
pubmed-meshheading:17663737-Adult,
pubmed-meshheading:17663737-Aged,
pubmed-meshheading:17663737-Aged, 80 and over,
pubmed-meshheading:17663737-Antithrombin III,
pubmed-meshheading:17663737-Arthroplasty, Replacement, Hip,
pubmed-meshheading:17663737-Dose-Response Relationship, Drug,
pubmed-meshheading:17663737-Drug Administration Schedule,
pubmed-meshheading:17663737-Enoxaparin,
pubmed-meshheading:17663737-Female,
pubmed-meshheading:17663737-Humans,
pubmed-meshheading:17663737-Male,
pubmed-meshheading:17663737-Middle Aged,
pubmed-meshheading:17663737-Treatment Outcome,
pubmed-meshheading:17663737-Venous Thrombosis
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.
|
|
pubmed:affiliation |
Department of Orthopaedics, Sahlgrenska University/Ostra Hospital, Gothenburg, Sweden. b.eriksson@orthop.gu.se
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
